Vijaya Diagnostic Centre Q2 FY26: Capex ₹160 Cr
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹202Cr
- +10.4% YoY
- +7.4% QoQ
- Net profit
- ₹43Cr
- +2.4% YoY
- +10.3% QoQ
- Margin
- 41%
- −1 pp YoY
- +2 pp QoQ
Guidance rank: #28 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.
From Vijaya Diagnostic Centre Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Vijaya Diagnostic Centre targets around 15% overall year-level growth.
- Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%.
- Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term.
- Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology.
- Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier.
- Pune hubs expected to break even within about a year; some cleanup activities delayed ramp-up.
- Despite seasonality and weather factors impacting pathology volumes temporarily, the company is optimistic on steady normalized growth.
2 more points from Vijaya Diagnostic Centre Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Vijaya Diagnostic Centre Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
- FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26.
- CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets.
- Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26.
- Plans to increase hubs from current two to five by end of FY27.
- Long-term expansion plan includes lease properties for new hubs/spokes.
2 more points from Vijaya Diagnostic Centre Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vijaya Diagnostic Centre Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Vijaya Diagnostic Centre Ltd said on order book & pipeline — free account, 30 seconds.
Vijaya Diagnostic Centre Ltd — Quarterly revenue & net profit
Vijaya Diagnostic Centre Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 202 | 183 | +10.4% | 188 | +7.4% |
| Operating profit (EBITDA) | 82 | 76 | +7.9% | 74 | +10.8% |
| Operating margin | 41% | 42% | -1 pp | 39% | +2 pp |
| Profit before tax | 58 | 57 | +1.8% | 52 | +11.5% |
| Net profit (PAT) | 43 | 42 | +2.4% | 39 | +10.3% |
| EPS (₹) | 4.21 | 4.10 | +2.7% | 3.76 | +12% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹255 Cr, net profit ₹59 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vijaya Diagnostic Centre's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medicare (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Vijaya Diagnostic Centre Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vijaya Diagnostic Centre Ltd Q2 FY26 results?
Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.
What is Vijaya Diagnostic Centre Ltd share price analysis?
Vijaya Diagnostic Centre Ltd currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹14,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vijaya Diagnostic Centre Ltd planning capital expenditure?
FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
Keep Vijaya Diagnostic Centre Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
